Much progress has been made in the treatment of primary breast cancer, particularly when there is a known mutation or overexpression that can be directly targeted (e.g. PI3K, CDK4/6, PARP, PD-L1) or with hormone receptor-positive disease (e.g. ER+, PR+, HER2+) (26). This evidence concerns the gene NR4A1 and breast cancer.